FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309604074> ?p ?o ?g. }

• W4309604074 abstract "Background: There is currently still a lack of effective therapeutic manner after the failure of first-line therapy for patients with advanced or metastatic gastric cancer. The present study aimed to evaluate the clinical efficacy and safety of different treatment strategies as second-line or above therapy for patients with advanced or metastatic gastric cancer. Methods: This was an observational multicenter real-world study. From January 2018 to December 2020, advanced or metastatic gastric cancer patients who have failed prior therapy were enrolled and treated with chemotherapy, anti-angiogenic TKIs (tyrosine kinase inhibitors) + chemotherapy or TKIs + ICIs (immune checkpoint inhibitors). In this study, progression free survival (PFS) was the primary end-point. Other evaluation indicators were objective response rate (ORR), disease control rate (DCR), overall survival (OS) and drug toxicities. Results: 162 patients were enrolled, of which 61 patients received chemotherapy, 47 patients received TKIs plus chemotherapy, and 54 patients received TKIs + ICIs. No statistically significant difference existed in ORR among groups (16.4% vs. 19.1% vs. 18.5%, p = 0.924). Patients who received TKIs plus chemotherapy obtained better DCR compared with the chemotherapy group (78.7% vs. 54.1%, p = 0.008), and simultaneously, the median PFS (3.3 m vs. 2.8 m, p = 0.001) and OS (8.0 m vs. 5.8 m, p = 0.005) in TKIs plus chemotherapy group were superior to chemotherapy group. Consistent results were observed in subgroup analysis, including sex, age, ECOG, number of metastatic sites and treatment line. No statistically differences were found between TKIs + ICIs and the chemotherapy group concerning DCR (63.0% vs. 54.1%, p = 0.336), median PFS (3.0 m vs. 2.8 m, p = 0.051) and OS (5.2 m vs. 5.8 m, p = 0.260). Different treatment manner present a special spectrum of adverse events (AEs), and the incidence of Grade 3-4 AEs were 31.1%, 38.3% and 18.5%, respectively. Conclusion: Compared with chemotherapy, anti-angiogenic TKIs plus chemotherapy demonstrated superior second-line or above therapeutic efficacy for advanced or metastatic gastric cancer with well tolerated toxicity. However, TKIs + ICIs failed to demonstrate a clinical advantage over chemotherapy." @default.
• W4309604074 created "2022-11-28" @default.
• W4309604074 creator A5010684363 @default.
• W4309604074 creator A5015505343 @default.
• W4309604074 creator A5015995069 @default.
• W4309604074 creator A5017445578 @default.
• W4309604074 creator A5020745851 @default.
• W4309604074 creator A5049796978 @default.
• W4309604074 creator A5056429685 @default.
• W4309604074 creator A5061742511 @default.
• W4309604074 creator A5070319888 @default.
• W4309604074 creator A5071168196 @default.
• W4309604074 creator A5071404557 @default.
• W4309604074 creator A5084028248 @default.
• W4309604074 date "2022-11-17" @default.
• W4309604074 modified "2023-10-13" @default.
• W4309604074 title "Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study" @default.
• W4309604074 cites W2011120267 @default.
• W4309604074 cites W2012039821 @default.
• W4309604074 cites W2028794391 @default.
• W4309604074 cites W2079195634 @default.
• W4309604074 cites W2097820456 @default.
• W4309604074 cites W2100439220 @default.
• W4309604074 cites W2111237964 @default.
• W4309604074 cites W2171075804 @default.
• W4309604074 cites W2276228008 @default.
• W4309604074 cites W2492927672 @default.
• W4309604074 cites W2577864197 @default.
• W4309604074 cites W2763064222 @default.
• W4309604074 cites W2785838318 @default.
• W4309604074 cites W2792441445 @default.
• W4309604074 cites W2793364080 @default.
• W4309604074 cites W2886354380 @default.
• W4309604074 cites W2894279338 @default.
• W4309604074 cites W2958083922 @default.
• W4309604074 cites W3011972925 @default.
• W4309604074 cites W3020689019 @default.
• W4309604074 cites W3038957077 @default.
• W4309604074 cites W3085086150 @default.
• W4309604074 cites W3127772819 @default.
• W4309604074 cites W3128646645 @default.
• W4309604074 cites W3129730716 @default.
• W4309604074 cites W3135622949 @default.
• W4309604074 cites W3153473864 @default.
• W4309604074 cites W3183289078 @default.
• W4309604074 cites W3200675468 @default.
• W4309604074 cites W3207973328 @default.
• W4309604074 cites W4200627750 @default.
• W4309604074 cites W4214916074 @default.
• W4309604074 cites W4220934838 @default.
• W4309604074 cites W4223618464 @default.
• W4309604074 cites W4225142403 @default.
• W4309604074 cites W4226075276 @default.
• W4309604074 doi "https://doi.org/10.3389/fphar.2022.1043217" @default.
• W4309604074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36467052" @default.
• W4309604074 hasPublicationYear "2022" @default.
• W4309604074 type Work @default.
• W4309604074 citedByCount "0" @default.
• W4309604074 crossrefType "journal-article" @default.
• W4309604074 hasAuthorship W4309604074A5010684363 @default.
• W4309604074 hasAuthorship W4309604074A5015505343 @default.
• W4309604074 hasAuthorship W4309604074A5015995069 @default.
• W4309604074 hasAuthorship W4309604074A5017445578 @default.
• W4309604074 hasAuthorship W4309604074A5020745851 @default.
• W4309604074 hasAuthorship W4309604074A5049796978 @default.
• W4309604074 hasAuthorship W4309604074A5056429685 @default.
• W4309604074 hasAuthorship W4309604074A5061742511 @default.
• W4309604074 hasAuthorship W4309604074A5070319888 @default.
• W4309604074 hasAuthorship W4309604074A5071168196 @default.
• W4309604074 hasAuthorship W4309604074A5071404557 @default.
• W4309604074 hasAuthorship W4309604074A5084028248 @default.
• W4309604074 hasBestOaLocation W43096040741 @default.
• W4309604074 hasConcept C121608353 @default.
• W4309604074 hasConcept C126322002 @default.
• W4309604074 hasConcept C143998085 @default.
• W4309604074 hasConcept C203092338 @default.
• W4309604074 hasConcept C2776694085 @default.
• W4309604074 hasConcept C535046627 @default.
• W4309604074 hasConcept C71924100 @default.
• W4309604074 hasConceptScore W4309604074C121608353 @default.
• W4309604074 hasConceptScore W4309604074C126322002 @default.
• W4309604074 hasConceptScore W4309604074C143998085 @default.
• W4309604074 hasConceptScore W4309604074C203092338 @default.
• W4309604074 hasConceptScore W4309604074C2776694085 @default.
• W4309604074 hasConceptScore W4309604074C535046627 @default.
• W4309604074 hasConceptScore W4309604074C71924100 @default.
• W4309604074 hasFunder F4320330351 @default.
• W4309604074 hasLocation W43096040741 @default.
• W4309604074 hasLocation W43096040742 @default.
• W4309604074 hasLocation W43096040743 @default.
• W4309604074 hasOpenAccess W4309604074 @default.
• W4309604074 hasPrimaryLocation W43096040741 @default.
• W4309604074 hasRelatedWork W167319750 @default.
• W4309604074 hasRelatedWork W2322192213 @default.
• W4309604074 hasRelatedWork W2369677035 @default.
• W4309604074 hasRelatedWork W2390837439 @default.
• W4309604074 hasRelatedWork W2409070295 @default.
• W4309604074 hasRelatedWork W2418514741 @default.
• W4309604074 hasRelatedWork W2420090748 @default.
• W4309604074 hasRelatedWork W2520320830 @default.

• next